Continuous-flow synthesis of 1,4,6,7-tetrahydro-5H-[1,2,3]triazolo[4,5-c]pyridines towards key intermediates of clinical candidates JNJ-54175446 and zanvipixant (JNJ-55308942) with antidepressant activity

RSC Adv. 2025 Jul 16;15(31):25202-25208. doi: 10.1039/d5ra03780h. eCollection 2025 Jul 15. ABSTRACT 1,4,6,7-Tetrahydro-5H-[1,2,3]triazolo[4,5-c]pyridines are potent antagonists of the P2X7 receptor, a key regulator of neuroinflammation associated with depression. Two...